Abstract
Aim of the work
To compare the expression of serum interleukin 33 (IL33), a new member of the interleukin1 (IL-1) cytokine family, in rheumatoid arthritis (RA) versus osteoarthritis (OA) patients and to correlate it with clinical, laboratory and radiographic parameters.
Subjects and methods
20 RA and 20 primary knee OA patients. The levels of serum IL-33 were measured by enzyme-linked immunosorbent assay (ELISA) while anticyclic citrullinated peptide (Anti-CCP), rheumatoid factor (RF), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were measured by standard laboratory techniques. Plain x-ray of both hands and wrists were evaluated using the modified Larsen score 1995 (MLS) in RA patients. Knee OA grading was performed according to the Kellgren Lawrence classification. The correlation of IL-33 level with clinical, laboratory and radiological data of RA and OA was analyzed.
Results
Serum IL-33 level was significantly higher in RA than in OA patients (P< 0.001). This level was positively correlated with disease duration, clinical and laboratory markers of disease activity, impaired functional status and radiographic severity in RA while not in OA patients.
Conclusions
These findings support that IL-33 could have an essential proinflammatory role in the pathogenesis of RA and that IL-33 level may be a monitor of disease activity and severity. IL-33 may become therapeutic target for RA.
Article PDF
Similar content being viewed by others
References
Khurana R, Berney SM. Clinical aspects of rheumatoid arthritis. Pathophysiology 2015; 12:153–165.
Pelletier JP, Martel J. Therapeutic targets in osteoarthritis: from today to tomorrow with new imaging technology. Ann Rheum Dis 2003; 62:79–82.
Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23:479–490.
Palmer G, Talabot-Ayer D, Lamacchia C, Toy D, Seemayer CA, Viatte S, et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum 2009; 60:738–749.
Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008; 7:827–840.
Miller AM. Role of IL-33 in inflammation and disease. J Inflamm 2011; 8:22.
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. The 2010 Rheumatoid Arthritis Classification Criteria: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum 2010; 62:2569–2581.
Altman R, Asch E, Bloch D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the knee. Arthritis Rheum 1986; 29:1039–1049.
Prevoo ML, Hof MA, Kuper HH. Modified disease activity scores that include twenty eight- joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arth Rheum 1995; 38:44–48.
Maska L, Anderson J, Michaud K. Measures of functional status and quality of life in rheumatoid arthritis. Arthritis Care Res 2011; 63:S4–S13.
Hawker GA, Main S, Kendzerska T, French M. Visual Analogue Scales (VAS) for pain. Measures of adult pain. Arthritis Care Res 2011; 63: S240–S252.
Doyle D, Dieppe P, Jane S, Husskison E. An articular index for the assessment of osteoarthritis. Ann Rheum Dis 1981; 40:75–78.
Lequesne MG, Maheu E. Clinical and radiological evaluation of hip, knee and hand osteoarthritis. Aging Clin Exp Res 2003; 15: 380–390.
eBioscience Human IL-33 Platinum ELISA BMS2048/BMS2048TEN for research use only. http://www.ebioscience.com/human-il-33-platinum-elisa-kit.htm; 2015.
Larsen A. How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in long term studies? J Rheumatol 1995; 22:1974–1975.
Brandt KD, Fife RS, Braunste in EM, Katz B. Radiographic grading of the severity of knee osteoarthritis: relation of the Kellgren and Lawrence grade to a grade based on joint space narrowing, and correlation with arthroscopic evidence of articular cartilage degeneration. Arthritis Rheum 1991; 34: 1381–1386.
Dawson-Saunders B, Trapp R. Basic and clinical biostatistics. 2nd ed. New York: Lange Medical Book: Prentice-Hall International Inc.; 1994.
Xiangyang Z, Lutian Y, Lin Z, Liping X, Hui S, Jing L. Increased levels of interleukin-33 associated with bone erosion and interstitial lung diseases in patients with rheumatoid arthritis. Cytokine 2012; 58:6–9.
Talabot-Ayer D, McKee T, Gindre P, Bas S, Baeten DL, Gabay C, et al. Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine 2012; 79:32–37.
Matsuyama Y, Okazaki H, Tamemoto H, Kimura H, Kamata Y, Nagatani K, et al. Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. J Rheumatol 2010; 37:18–25.
Tang S, Huang H, Hu F, Zhou W, Guo J, Jiang H, et al. Increased IL-33 in synovial fluid and paired serum is associated with disease activity and autoantibodies in RA. Clin Dev Immunol 2013; 2013:985301.
Mu R, Huang HQ, Li YH, Li C, Ye H, Li ZG. Elevated serum interleukin 33 is associated with autoantibody production in patients with rheumatoid arthritis. J Rheumatol 2010; 37:2006–2013.
Ali OS, Khalifa AI, Atia HA. Levels of interleukin 33 and interleukin 27 in rheumatoid arthritis and osteoarthritis in Egyptian patients. Int J Adv Biotechnol Res 2014; l5:465–473.
Hong YS, Moon SJ, Joo YB, Jeon CH, Cho ML, Ju JH, et al. Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. J Korean Med Sci 2011; 26:1132–1139.
Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 2002; 297:1689–1692.
Xu D, Jiang HR, Li Y, Pushparaj PN, Kurowska-Stolarska M, Leung BP, et al. IL-33 exacerbates autoantibody-induced arthritis. J Immunol 2010; 184:2620–2626.
Author information
Authors and Affiliations
Corresponding author
Additional information
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Abd El-Aziz Farag, A.M., El-Gazzar, N.M., Abo El Hawa, M.A. et al. Study of interleukin 33 in rheumatoid arthritis versus osteoarthritis patients. Egypt Rheumatol Rehabil 44, 159–163 (2017). https://doi.org/10.4103/err.err_8_17
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.4103/err.err_8_17